D83.2
BillableCommon variable immunodeficiency with autoantibodies to B- or T-cells
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D83.2 an HCC code?
Yes. D83.2 maps to Severe Combined Immunodeficiency and Other Immune Disorders under the CMS-HCC V28 risk adjustment model (and Disorders of Immunity under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D83.2
For D83.2 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D83.2 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D83.2 is the ICD-10-CM diagnosis code for common variable immunodeficiency with autoantibodies to b- or t-cells. A common immune disorder where the body produces antibodies that attack its own B or T immune cells, weakening the immune system. D83.2 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering certain disorders involving the immune mechanism (d80-d89).
Under the CMS-HCC V28 risk adjustment model, D83.2 maps to Severe Combined Immunodeficiency and Other Immune Disorders (HCC 114) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, D83.2 maps to Disorders of Immunity (HCC 47) with a community, non-dual, aged base RAF weight of 0.472. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Document the presence of autoantibodies with specific testing results (e.g., anti-B cell or anti-T cell antibodies). Because D83.2 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D83.2 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Document the presence of autoantibodies with specific testing results (e.g., anti-B cell or anti-T cell antibodies)
- •This code indicates an autoimmune component; document any associated autoimmune manifestations
Clinical Significance
Common variable immunodeficiency with autoantibodies to B- or T-cells represents a form of common variable immunodeficiency where the immune system produces antibodies that attack its own lymphocytes, contributing to the immunodeficiency through autoimmune destruction of B-cells or T-cells. This autoimmune component adds complexity to management and increases the risk of other autoimmune manifestations.
Documentation Requirements
- ✓Documentation must include serological evidence of autoantibodies directed against B-cells or T-cells, immunoglobulin levels confirming hypogammaglobulinemia, lymphocyte subset analysis, and documentation of any associated autoimmune cytopenias or other autoimmune conditions.
- ✓Describe the relationship between the autoantibodies and the clinical immunodeficiency, and include treatment approach addressing both immunodeficiency and autoimmune components.